담도암 : 시장 인사이트, 역학 및 시장 예측(2036년)

Cholangiocarcinoma (CCA) Insights and Trends

• About 10,000 people in the United States develop cholangiocarcinoma each year.
• As per the National Organization for Rare Disorders (NORD), the incidence of intrahepatic CCA in the US is approximately 1.50 per 100,000 people. Recently, the incidence of bile duct cancers has been increasing.
• Nearly two-thirds of patients with cholangiocarcinoma are aged 65 years or older at diagnosis, with the average age being around 70 years for intrahepatic bile duct cancer and 72 years for extrahepatic (perihilar or distal) disease.
• Currently, the only potentially curative treatment is surgery. However, this is only an option in approximately 25% of patients.Whereas, for advanced disease, systemic therapy is the mainstay, including chemotherapy and immunotherapy.
• A few of the companies involved in marketed therapies for CCA include Jazz Pharmaceuticals (ZIIHERA), Incyte Corporation (PEMAZYRE), Servier (TIBSOVO), and others.
• Pharmaceutical companies developing therapies for CCA include TransThera Sciences (tinengotinib), Senhwa Biosciences (silmitasertib), Tyra Biosciences (TYRA-200), and others.
• Pipeline innovation in CCA is increasingly focused on overcoming resistance and expanding targetable populations. Emerging small molecules include HER2 inhibitors, BRAF/MEK inhibitors, and novel combination regimens integrating immunotherapy.
• Survival outcomes in bile duct cancer are largely influenced by the tumor's location and the stage at which it is diagnosed. Access to advanced treatment options, including participation in clinical trials, can also play an important role, as these studies may provide patients with newer therapies not yet available in standard care, potentially improving treatment outcomes.
• Despite progress, significant unmet needs remain with limited sensitivity of current biomarkers, and challenges in early detection contribute to late-stage diagnosis.

DelveInsight's 'Cholangiocarcinoma (CCA) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the CCA, historical and forecasted epidemiology, as well as the CCA market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Cholangiocarcinoma (CCA) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates CCA patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in CCA and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Cholangiocarcinoma (CCA) Market

Rising Incidence and Improved Diagnosis

The incidence of CCA is increasing globally, particularly in developed regions. Improved diagnostic techniques and greater disease awareness are leading to earlier detection and higher reported cases, driving treatment demand.

Shift Toward Precision Medicine

The growing use of molecular profiling has enabled the identification of actionable mutations such as FGFR2 fusions and IDH1 mutations. This has accelerated the adoption of targeted therapies, transforming treatment approaches from traditional chemotherapy to biomarker-driven strategies.

Expansion of Immunotherapy-Based Regimens

The integration of immune checkpoint inhibitors into first-line and combination regimens is improving survival outcomes. Ongoing trials are further exploring immunotherapy combinations, strengthening their role in the CCA treatment paradigm.

Cholangiocarcinoma (CCA) Understanding and Treatment Algorithm

Cholangiocarcinoma (CCA) Overview and Diagnosis

CCA is a rare and aggressive malignancy arising from the epithelial cells of the bile ducts, which can occur within the liver (intrahepatic), at the hilum (perihilar), or outside the liver (distal). It is often diagnosed at an advanced stage due to non-specific early symptoms such as jaundice, abdominal pain, weight loss, and fatigue, leading to poor prognosis and limited curative options. The disease is also collectively referred to as biliary tract cancer (BTC), associated with significant clinical heterogeneity and high rates of recurrence even after treatment.

Diagnosis of CCA involves a combination of imaging, laboratory, and histopathological evaluation. Imaging modalities such as CT, MRI/MRCP, and ultrasound are used to identify tumor location and extent, while tumor markers like CA 19-9 may support suspicion but are not definitive. Confirmation is achieved through biopsy or cytology, and molecular profiling is increasingly used to identify actionable mutations such as FGFR2 fusions and IDH1 mutations to guide targeted therapy selection.

Current Cholangiocarcinoma (CCA) Treatment Landscape

Treatment of CCA depends on stage and resectability. Surgical resection remains the only potentially curative option for early-stage disease, often followed by adjuvant chemotherapy. For advanced or metastatic disease, systemic chemotherapy (commonly gemcitabine and cisplatin-based regimens) is standard, while immunotherapy combinations have recently improved outcomes in first-line settings. Targeted therapies such as FGFR inhibitors and IDH1 inhibitors are used in biomarker-selected patients, and emerging biologics and combination regimens continue to reshape the treatment landscape.

Cholangiocarcinoma (CCA) Unmet Needs

The section "unmet needs of CCA" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited curative treatment options

2. High disease heterogeneity and resistance

3. Need for more targeted and personalized therapies

4. Early detection and diagnosis, and others.....

Cholangiocarcinoma (CCA) Epidemiology

Key Findings from Cholangiocarcinoma (CCA) Epidemiological Analysis and Forecast

• CCA most commonly occurs between the ages of 60 and 70 and is more frequently seen in males.
• As per secondary analysis, the Incidence of CCA in Italy, Germany, UK and US is ~3.4, ~3, ~2.2, and ~1.5 per 100,000 population.
• CCA accounts for ~10-15% of primary liver tumors and 3% gastrointestinal cancers.
• CCA accounts for up to 15 % of primary hepatobiliary malignancies. In Europe, CCA incidence rates range from 0.4-1.8 per 100,000 population, while in the US, rates range from 0.6-1 per 100,000 population.
• In 2025, Germany recorded the highest number of incident CCA cases among the EU4 and UK countries. According to DelveInsight's projections, this number is expected to increase by 2036.

Cholangiocarcinoma (CCA) Drug Analysis & Competitive Landscape

The CCA drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase II/I-II clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships, upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the CCA treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the CCA therapeutics market.

Approved Therapies for Cholangiocarcinoma (CCA)

Zanidatamab (ZIIHERA): Jazz Pharmaceuticals

Zanidatamab (ZIIHERA) is a first-in-class, dual HER2-targeted bispecific antibody approved for the treatment of patients with HER2-positive biliary tract cancers (including CCA). Zanidatamab works by binding to two distinct extracellular domains of the HER2 receptor, leading to receptor internalization and enhanced anti-tumor activity through multiple immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Zanidatamab is only approved in the US and not anywhere else in the world.

Pemigatinib (PEMAZYRE): Incyte Corporation

PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. In April 2020, the US FDA granted accelerated approval to PEMAZYRE for cholangiocarcinoma with an FGFR2 rearrangement or fusion. In 2021, Japanese MHLW approved PEMAZYRE for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene.

Cholangiocarcinoma (CCA) Pipeline Analysis

Tinengotinib (TT-00420): TransThera Sciences

Tinengotinib (TT-00420), is a selective focused multi-kinase inhibitor, self-developed by the Company with global intellectual property rights, primarily targeting three key pathways (namely, FGFR/VEGFR, JAK, and Aurora kinases). It was granted the Orphan Drug Designation (ODD) in 2019 and Fast Track Desigantion (FTD) in 2021 by the FDA for the treatment of CCA. According to the company's annual report 2025, the organization plans to start with the commercialization of Tinengotinib for FGFR inhibitor relapsed or refractory CCA in China and then plans to promote the launch of the drug in the US and the EU, covering the same indication.

Silmitasertib (CX-4945): Senhwa Biosciences

Silmitasertib (CX-4945), a synthetically derived small molecule, is provided as a sodium salt in hard gelatin capsule shells for oral administration. CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents.

Cholangiocarcinoma (CCA) Key Players, Market Leaders and Emerging Companies

• Jazz Pharmaceuticals
• Incyte Corporation
• Servier
• Merck
• TransThera Sciences
• Senhwa Biosciences
• Tyra Biosciences
• Lisata Therapeutics, and others

Cholangiocarcinoma (CCA) Drug Updates

• In December 2025, TransThera Sciences announced the publication of clinical results from a US-based Phase II trial evaluating tinengotinib in patients with CCA in The Lancet Gastroenterology and Hepatology.
• In October 2025, TransThera Sciences presented the pooled study data of Tinengotinib for CCA at the 2025 ESMO annual conference. The study showed that Tinengotinib was well tolerated and its safety was controllable.
• In January 2025, TransThera Sciences delivered a poster presentation on the overall survival results and biomarker correlation analysis data from a Phase II study of Tinengotinib in patients with advanced/metastatic cholangiocarcinoma at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
• In January 2025, Senhwa Biosciences announces that promising clinical data from their phase I/II trial, evaluating the combination of Silmitasertib plus Gemcitabine and Cisplatin compared to Gemcitabine and Cisplatin alone in the frontline treatment of patients with CCA will be presented at the 2021 ASCO GI Cancers Symposium in San Francisco. The study met its primary endpoint during an interim analysis. The findings indicate a clinically meaningful improvement in progression-free survival (PFS).

Cholangiocarcinoma (CCA) Market Outlook

The CCA market (2022-2036 forecast) treatment landscape has begun to evolve with the advent of precision oncology and immunotherapy. A major milestone was the approval of PEMAZYRE for previously treated patients with FGFR2 fusion or rearrangement-positive CCA, marking a shift toward biomarker-driven therapy. Additionally, TOBSOVO has been approved for patients with IDH1-mutated cholangiocarcinoma, further reinforcing the role of genomic profiling in treatment selection.

The pipeline for CCA remains robust, with multiple mechanism-driven therapies and combination strategies in clinical development. The pipeline for CCA is expanding, with several promising investigational therapies targeting key oncogenic pathways. These include tinengotinib, a multi-kinase inhibitor,silmitasertib, which targets CK2, and TYRA-200, a next-generation FGFR2-selective inhibitor. In addition, ongoing research is evaluating HER2-targeted therapies, antibody-drug conjugates, and novel combination regimens to further improve outcomes.

Overall, the uptake of targeted therapies, expansion of immunotherapy into earlier lines, and continued innovation in biomarker-driven treatment approaches are expected to drive steady growth in the 7MM CCA market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• The United States is expected to witness significant growth and account for the largest share of the cholangiocarcinoma market across the 7MM.
• The entry of late-stage candidates such as Tinengotinib (TT-00420) is expected to intensify competition in the CCA treatment landscape during the latter half of the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Cholangiocarcinoma (CCA) (2022-2036 Forecast)

The CCA market comprises small molecules and monoclonal antibody, each targeting different aspects of CCA.

• Small molecules: Approved therapies such as pemigatinib and ivosidenib selectively inhibit oncogenic drivers, including FGFR2 fusions and IDH1 mutations, enabling personalized treatment approaches in previously treated patients. In parallel, pipeline candidates such as tinengotinib, silmitasertib, and TYRA-200 are advancing through clinical development, targeting resistance pathways, tumor proliferation, and kinase signaling networks.

Small molecules define the core innovation landscape, with targeted therapies currently commercially validated and driving pipeline growth.

Cholangiocarcinoma (CCA) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the CCA drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in CCA is expected to vary based on clinical positioning, mechanism of action, and stage of development. Approved targeted therapy such as Zanidatamab (ZIIHERA) is projected to demonstrate relatively faster uptake, driven by its first-in-class dual HER2-targeted antibody.

In contrast, pipeline candidate Silmitasertib (CX-4945) is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved Therapies in Cholangiocarcinoma (CCA)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Cholangiocarcinoma (CCA) Therapies Price Scenario & Trends

Pricing and analogue assessment of CCA therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Cholangiocarcinoma (CCA)

To keep up with CCA market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the CCA emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in CCA, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Massachusetts General Hospital, Johns Hopkins University, and German Cancer Research Center, etc. were contacted.Their opinion helps understand and validate current and emerging CCA therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in CCA.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of CCA, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of CCA, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the CCA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM CCA market.

Report Insights

• Cholangiocarcinoma (CCA) Patient Population Forecast
• Cholangiocarcinoma (CCA) Therapeutics Market Size
• Cholangiocarcinoma (CCA) Pipeline Analysis
• Cholangiocarcinoma (CCA) Market Size and Trends
• Cholangiocarcinoma (CCA) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Cholangiocarcinoma (CCA) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Cholangiocarcinoma (CCA) Treatment Addressable Market (TAM)
• Cholangiocarcinoma (CCA) Competitive Landscape
• Cholangiocarcinoma (CCA) Major Companies Insights
• Cholangiocarcinoma (CCA) Price Trends and Analogue Assessment
• Cholangiocarcinoma (CCA) Therapies Drug Adoption/Uptake
• Cholangiocarcinoma (CCA) Therapies Peak Patient Share Analysis

Report Assessment

• Cholangiocarcinoma (CCA) Current Treatment Practices
• Cholangiocarcinoma (CCA) Unmet Needs
• Cholangiocarcinoma (CCA) Clinical Development Analysis
• Cholangiocarcinoma (CCA) Emerging Drugs Product Profiles
• Cholangiocarcinoma (CCA) Market attractiveness
• Cholangiocarcinoma (CCA) Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the CCA market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of CCA?
• What are the disease risks, burdens, and unmet needs of CCA? What will be the growth opportunities across the 7MM concerning the patient population with CCA?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of CCA? What are the current guidelines for treating CCA in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CCA market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of Cholangiocarcinoma (CCA)

6. Cholangiocarcinoma (CCA) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Cholangiocarcinoma (CCA) By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Cholangiocarcinoma (CCA) By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Cholangiocarcinoma (CCA)

• 7.1. Introduction
• 7.2. Causes
• 7.3. Signs And Symptoms
• 7.4. Diagnosis
  • 7.5.1. Differential Diagnosis
  • 7.5.2. Diagnostic Algorithm
  • 7.5.3. Diagnostic Guidelines
• 7.6. Treatment and Management
• 7.7. Treatment Algorithm

8. Epidemiology and Patient Population of Cholangiocarcinoma (CCA)

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Incident Cases of Cholangiocarcinoma (CCA) in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of Cholangiocarcinoma (CCA) in the United States
  • 8.4.2. Tumor Location-specifc Incident Cases of Cholangiocarcinoma (CCA) in the United States
  • 8.4.3. Stage-specific Incident Cases of Cholangiocarcinoma (CCA) in the United States
  • 8.4.4. Age-specific Incident Cases of Cholangiocarcinoma (CCA) in the United States
  • 8.4.5. Mutation-specific Incident Cases of Cholangiocarcinoma (CCA) in the United States
  • 8.4.6. Total Treated Cases of Cholangiocarcinoma (CCA) in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 8.5.2. Tumor Location-specifc Incident Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 8.5.3. Stage-specific Incident Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 8.5.4. Age-specific Incident Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 8.5.5. Mutation-specific Incident Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 8.5.6. Total Treated Cases of Cholangiocarcinoma (CCA) in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of Cholangiocarcinoma (CCA) in Japan
  • 8.6.2. Tumor Location-specifc Incident Cases of Cholangiocarcinoma (CCA) in Japan
  • 8.6.3. Stage-specific Incident Cases of Cholangiocarcinoma (CCA) in Japan
  • 8.6.4. Age-specific Incident Cases of Cholangiocarcinoma (CCA) in Japan
  • 8.6.5. Mutation-specific Incident Cases of Cholangiocarcinoma (CCA) in Japan
  • 8.6.6. Total Treated Cases of Cholangiocarcinoma (CCA) in Japan

9. Patient Journey of Cholangiocarcinoma (CCA)

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Cholangiocarcinoma (CCA)
• 10.2. Zanidatamab (ZIIHERA): Jazz Pharmaceuticals
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views
• 10.3. Pemigatinib (PEMAZYRE): Incyte Corporation
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.3. Summary of Pivotal Trials
  • 10.3.4. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of Cholangiocarcinoma (CCA)
• 11.2. Tinengotinib (TT-00420): TransThera Sciences
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. Silmitasertib (CX-4945): Senhwa Biosciences
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
    • 11.3.3.1. Clinical Trial Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst Views

12. Cholangiocarcinoma (CCA): Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Cholangiocarcinoma (CCA)
• 12.3. Conjoint Analysis of Cholangiocarcinoma (CCA)
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Cholangiocarcinoma (CCA) in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of Cholangiocarcinoma (CCA) in the United States
  • 12.6.2. Market Size of Cholangiocarcinoma (CCA) by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Cholangiocarcinoma (CCA) in EU4 and the UK
  • 12.7.2. Market Size of Cholangiocarcinoma (CCA) by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Cholangiocarcinoma (CCA) in Japan
  • 12.8.2. Market Size of Cholangiocarcinoma (CCA) by Therapies in Japan

13. Unmet Needs of Cholangiocarcinoma (CCA)

14. SWOT Analysis of Cholangiocarcinoma (CCA)

15. KOL Views of Cholangiocarcinoma (CCA)

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Cholangiocarcinoma (CCA)

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Cholangiocarcinoma (CCA) Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight